Cargando…
CSE1L, as a novel prognostic marker, promotes pancreatic cancer proliferation by regulating the AKT/mTOR signaling pathway
Pancreatic cancer is one of the most aggressive tumors with poor prognosis and new targetable therapies are urgently required. CSE1L (chromosome segregation 1 like) is thought to play an important role in tumorigenesis and acts as a cancer therapeutic target. However, the biological function and the...
Autores principales: | Zhang, Xiao, Zhang, Xiaofei, Mao, Tiebo, Xu, Haiyan, Cui, Jiujie, Lin, Hechun, Wang, Liwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040880/ https://www.ncbi.nlm.nih.gov/pubmed/33854580 http://dx.doi.org/10.7150/jca.54482 |
Ejemplares similares
-
HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53
por: Mao, Tiebo, et al.
Publicado: (2022) -
Distinguishable Prognostic Signatures and Tumor Immunogenicity Between Pancreatic Head Cancer and Pancreatic Body/Tail Cancer
por: Ge, Weiyu, et al.
Publicado: (2022) -
Cuproptosis‐related lncRNAs are correlated with tumour metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients
por: Wang, Yanling, et al.
Publicado: (2023) -
A Novel Molecular Signature of Cancer-Associated Fibroblasts Predicts Prognosis and Immunotherapy Response in Pancreatic Cancer
por: Ge, Weiyu, et al.
Publicado: (2022) -
A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated advanced pancreatic cancer
por: Yao, Jiayu, et al.
Publicado: (2021)